Full-Time

Director – Analytics and Insights Lead

Regulatory Affairs Resource

Updated on 7/22/2026

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$191.3k - $272.3k/yr

+ Discretionary Annual Bonus + Discretionary Stock-based Long-term Incentives

No H1B Sponsorship

San Mateo, CA, USA + 1 more

More locations: Parsippany-Troy Hills, NJ, USA

In Person

On-site required in Parsippany, NJ and Foster City, CA.

US Top Secret Clearance Required

Category
Legal & Compliance (1)
Required Skills
Forecasting

Get referred to Gilead Sciences

Find people who can refer or advise you

Requirements
  • MA / MS / MPH with 10+ years of Regulatory Affairs, resource and/or project management OR 8+ years with a PhD with relevant experience OR a BA / BS with 12+ years Regulatory Affairs, resource and/or project management.
  • Experience managing complex projects and implementations.
  • Planisware, Smartsheet (including Resource Manager, Control Center), or other named resourcing experience required.
  • Knowledge of resourcing and forecasting methods and applicable tools for tracking and forecasting needs.
  • Strong understanding of the research and drug development life cycle processes, roles and systems required.
  • Ability to influence and drive decisions without direct authority.
  • Demonstrated negotiation, problem solving, critical thinking and facilitation skills.
  • Strong quantitative reasoning and analytical ability.
  • History of motivating others with a positive attitude to deliver to important milestones while maintaining a positive, transparent, and collaborative team environment.
  • Ability to establish priorities, operate with a sense of urgency and collaborate (interpersonal, relationship management) with cross functional team members.
  • Ability to proactively gather, interpret and evaluate information from a variety of resources to make decisions and recommendations.
  • Proven ability to multitask in order of priority in a deadline driven environment with optimal efficiency and accuracy.
  • Ability to communicate in a clear and concise manner.
  • Ability to support a team-oriented, highly matrixed environment.
  • Ability to execute multiple tasks as assigned.
  • When needed, ability to travel.
  • People Leader Accountabilities: Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • People Leader Accountabilities: Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential. They ensure employees are receiving the feedback and insight needed to grow, develop and realize their purpose.
  • People Leader Accountabilities: Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account. They provide the support needed to remove barriers and connect their team to the broader ecosystem
Responsibilities
  • Own the data quality, infrastructure, and business practices related to resource management.
  • Leads special projects and pilots that advance the capabilities of RA Business Operations.
  • Provide support across Business Operations capabilities as needed (Vendor Management, Business Process Excellence, Inspection Readiness, Business Process Excellence, Change Management, Communications and Engagement)
  • Makes significant contributions to short- and long-range RA strategies, plans, and infrastructure development, and Development, RSQ and RA-wide initiatives and evolutions.
  • Collaborate within Human Capital (Resource Management and Vendor Management) to drive holistic internal/external resourcing strategies across RA
  • Embed resource management concepts and influence the culture and practices across RA as it pertains to managing demand, increasing capacity, developing talent in line with strategy, and creative solutioning.
  • Build relationships and trust with a network of leaders and sub-functional spoke contacts to influence and deliver the goals of resource management and Business Operations
  • Manage difficult conversations including headcount discussions, prioritization, and interrogation of data quality
  • Lead yearly Strategic Workforce Planning cycles in partnership with Head of Human Capital. Track and drive changes to address gaps identified in workforce.
  • Oversee the maintenance of algorithmic forecasting (Planisware) in collaboration with others on the Human Capital team to improve algorithm accuracy and leadership understanding of resource trends.
  • Orchestrate across RA leadership, Finance (LE cycles) and HR to enable the workforce needed to drive our portfolio.
  • Aligns resource data and planning efforts to facilitate decision-making forums, including capacity planning and initiative review meetings.
  • Provides guidance and recommendations, based on data, of the future resource needs for latest estimate/year end processes, etc. for Regulatory Affairs functional areas as needed. This role is the consultant to the business on all things resourcing related.
  • Partners with the Regulatory Affairs Leadership Team to develop mitigation plans to address gaps in demand and capacity in collaboration with the Human Capital Lead and Vendor Governance.
  • Provides formal and informal training of resource concepts, processes, tools, and reports.
  • Oversee technical administration of Planisware and Smartsheet Resource Manager tools in collaboration with Human Capital team members and Performance Excellence Infrastructure Lead
  • Continual improvement and maturation of Resource Management capability
  • Develop performance and resource management guidelines and training materials for team leads and project managers.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval in June 2026 for Trodelvy as first-line mTNBC treatment expands market to 75,000+ patients globally.
  • Trodelvy+Keytruda reduces progression or death risk by 35%, establishing new standard of care in first-line TNBC.
  • Gilead acquired Arcellx, Ouro Medicines, and Tubulis in 2026 to diversify oncology pipeline beyond HIV.

What critics are saying

  • AstraZeneca's Enhertu threatens Trodelvy's $2.8B oncology revenue target by 2028 with 50-54% progression risk reduction.
  • High debt with 0.89 debt-to-equity ratio constrains funding for additional oncology acquisitions after $21B Immunomedics deal.
  • Trodelvy's safety profile including leukopenia and anemia may trigger stricter reimbursement restrictions in 2026-2027.

What makes Gilead Sciences unique

  • Trodelvy is the first antibody-drug conjugate approved for first-line metastatic triple-negative breast cancer globally.
  • Gilead uniquely anchors its portfolio with HIV franchise generating 67% of revenue while building oncology as second engine.
  • Gilead holds patent protection for top HIV drugs until 2036, avoiding near-term patent cliffs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Good News Network
Jun 9th, 2026
Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection.

Staggering results show hiv-transmission reduced 100% with twice-yearly Lenacapavir injection. Jun 9, 2026 A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants. Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which in this case was Uganda or South Africa. The results were nothing short of extraordinary - 100% efficacy, not a single young woman contracted HIV. This was followed up by PURPOSE 2, which expanded the geographical area significantly to more countries on more continents, and expanded the pool of individuals from beyond just young women to men - and to those of all ages. 5,000 participants took part. The result was the same: 99.9% reduction in infection rates. Both were considered phase 3 clinical trials, and were conducted in a randomized, double-blinded protocol, but were not tested against a placebo. Instead, the Lenacapavir injections were compared to the current standard of HIV prevention - a pill called Truvada or Descovy taken daily. These both were also found to prevent HIV transmission by 99.9% during development, but must be taken every day to achieve this level of protection. As anyone who's tried to stick to a once-a-day pill regime long-term will agree, it's not an easy thing to maintain month after month. By contrast, the twice-yearly injections are much easier to adhere to, and they also come with the added benefit of removing the social stigma of being seen taking a daily pill and therefore at risk of HIV transmission. This can be particularly alleviating in high-HIV-prevalent countries where male homosexuality is illegal, such as Uganda. Indeed the superiority of a twice-yearly injection was so clear that both PURPOSE trials were halted early over ethical reasons. A 52-week follow-up screened for HIV developments. Lenacapavir was named by Science Magazine as the Breakthrough of the Year in 2024, and was approved by the FDA for use in humans under the brand name Yeztugo. It works to break down the HIVs capsid shell by binding to an "highly conserved" protein on the exterior. That means that no matter how many times or into what form the virus mutates, the exterior shell protein remains - presenting the perfect target for the drug. In layman's terms, the drug then works through the protein to disrupt the capsid shell, which the virus 'takes down' and 'builds up' several times during its lifecycle with perfect geometric precision. The disruption prevents the virus from completing its life cycle. Initial R&D, regulation compliance, and proof of efficacy and safety requirements mean that producing Lenacapavir has cost its developer, Gilead Sciences, an undisclosed total cost that would be reasonable to estimate at well over a billion dollars based on normal pharma development costs. Gilead has nevertheless committed to providing the drug at cost in certain low-income regions and has licensed generic manufacturers to produce it for approximately $40 per year in 120 low and middle-income countries starting in 2027.

AllSci
Apr 10th, 2026
Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access.

Tempus AI expands oncology data collaboration with Gilead Sciences through AI-driven platform access. April 10, 2026 Tempus AI, Inc. (Nasdaq: TEM), a Chicago-based technology company, announced an expanded multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at advancing Gilead's oncology pipeline through enterprise-wide access to Tempus's AI-driven Lens platform and multimodal real-world evidence datasets. The agreement covers multiple oncology indications; no specific drug candidates or therapeutic targets were disclosed as part of the transaction. Financial terms were not disclosed. Under the expanded arrangement, Gilead gains enterprise-wide access to the Tempus Lens platform, which integrates de-identified genomic, clinical, imaging, and outcomes data into a unified repository supported by AI-driven analytical tooling. Disclosed applications include trial design, indication selection, biomarker strategy, health outcomes analysis, and clinical real-world evidence generation. Tempus will also provide dedicated analytical services under the agreement. The collaboration represents an expansion of a pre-existing relationship in which Gilead had previously used Tempus data to inform oncology R&D initiatives, and follows on from a collaboration between Tempus and Daiichi Sankyo announced in March 2026. The collaboration is designed to operate across Gilead's oncology pipeline rather than in support of a single program. Gilead's oncology portfolio includes sacituzumab govitecan, axicabtagene ciloleucel, brexucabtagene autoleucel, and magrolimab, among other assets, though none were named as specific beneficiaries of the arrangement. The platform's stated functions - indication prioritization, patient stratification, biomarker pre-validation, and real-world evidence generation - are applicable across tumor types and development stages. Your email address will not be published. Required fields are marked *

Yahoo Finance
Apr 9th, 2026
Gilead exercises option on Kymera's oral CDK2 degrader KT-200, triggering $45M milestone

Kymera Therapeutics will receive a $45 million milestone payment following Gilead Sciences' decision to exercise its option to exclusively licence KT-200, a first-in-class oral CDK2 molecular glue degrader development candidate. Gilead will advance the programme into IND-enabling studies, targeting an IND filing in 2027. KT-200 is expected to become the first molecular glue discovered by Kymera to enter clinical trials. The drug candidate demonstrated low-nanomolar degradation of CDK2 in preclinical testing, with robust activity in cancer cell lines and favourable safety profiles. It targets cancers driven by CCNE1 amplification, including advanced breast cancer. Under their collaboration agreement, Kymera is eligible for up to $750 million in total payments and has received $85 million to date. The company will also receive tiered royalties on net product sales.

Genetic Engineering and Biotechnology News
Apr 7th, 2026
Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities.

Gilead to acquire Tubulis for up to $5B, expanding cancer ADC capabilities. April 7, 2026 Gilead Sciences has agreed to acquire German-based Tubulis for up to $5 billion, the companies said today, in a deal designed to expand the buyer's antibody-drug conjugate (ADC) capabilities with a focus on fighting cancer. Headquartered in Munich, privately held Tubulis has developed next-generation ADC candidates based on its own conjugation, linker and payload technologies intended to more selectively deliver diverse payloads to tumors deemed to be of high unmet need. The companies said Tubulis' programs and platforms have broad potential across multiple tumor types, complementing Gilead's development and commercialization expertise in oncology. "We like the strategic fit and deal terms of the Tubulis (private) acquisition," Daina M. Graybosch, PhD, senior managing director, immuno-oncology and a senior research analyst at Leerink Partners, wrote this morning in a research note. "This is more than an oncology bolt-on; we see real platform value in application of Tubulis' ADC technologies to other therapeutic areas, namely virology." Tubulis' lead pipeline candidate, TUB-040, is a sodium-dependent phosphate transport protein 2B (NaPi2b)-targeting topoisomerase-I inhibitor (TOPO1i) ADC that is now under study in the Phase Ib/II NAPISTAR1-01 trial (NCT06303505) assessing its safety, pharmacokinetics, and preliminary efficacy as a treatment for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). In October at the European Society for Medical Oncology (ESMO), Graybosch noted, Tubulis presented data for TUB-040 showing a confirmed 50% overall response rate (ORR) and a 60% unconfirmed ORR across dose levels and irrespective of target antigen - results that were competitive with more mature datasets from leading TOPO1i ADCs. "Though the dataset was early, and our primary outgoing question was how durability would mature, we suspect that Gilead saw durability maturing positively in their diligence," Graybosch added. "If TUB-040 proves active in NSCLC, the program could complement their Trodelvy and IO [immune-oncology] lung programs. We wonder if Gilead saw early clinical NSCLC data in their diligence and if excitement around the emerging signal drove some of Tubulis' valuation." Another Tubulis pipeline candidate, TUB-030, is a 5T4-targeting ADC that according to the companies has shown promising initial clinical data across various solid tumor types. TUB-030 is currently under study in the Phase I/IIa 5-STAR 1-01 trial (NCT06657222), a first-in-human study which aims to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TUB-030 as a monotherapy in patients with advanced solid tumors. Tubulis has said it is developing TUB-030 for up to 13 undisclosed solid tumor indications. Partners since 2024. The acquisition deal follows a two-year, up-to-$465 million collaboration with Tubulis launched in December 2024. Gilead gained access to Tubulis' Tubutecan and Alco5 platforms after signing an exclusive option and license agreement to discover and develop an ADC against a solid tumor target. At the time, Gilead agreed to pay Tubulis $20 million upfront, received an option that if exercised would have given Tubulis an additional $30 million - plus up to $415 million in payments tied to achieving development and commercialization milestones, as well as mid-single to low double-digit tiered royalties on sales of marketed products resulting from the collaboration. "Today's agreement follows a two-year collaboration with Tubulis, which has given us strong conviction in their programs and research capabilities," Gilead Chairman and CEO Daniel O'Day said in a statement. "The agreement to acquire Tubulis is a significant milestone in Gilead's progress in oncology. The company brings a clinical-stage candidate that is a potential new treatment for ovarian cancer, as well as a next-generation ADC platform and a promising early pipeline." "Bringing this potential into Gilead would further expand what is already the strongest and most diverse pipeline in our company's history," O'Day declared. Investors appeared less enthusiastic about the acquisition, as shares of Gilead dipped 1.7% in early Tuesday trading to $137.80 as of 12:01 p.m. ET. Tubulis is Gilead's third announced acquisition this year. The biotech giant announced plans in March to buy Ouro Medicines for up to $2.18 billion, and in February agreed to acquire Arcellx for up to $7.8 billion - for which it agreed last week to extend its tender offer until 5 p.m. ET on April 24. Under the acquisition deal, Gilead agreed to acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash payable at closing, and up to $1.85 billion in payments tied to milestones. The transaction is expected to close in the second quarter subject to expiration or termination of specified regulatory filings and other customary conditions. Upon closing of the deal, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing, and clinical capabilities to advance next generation ADCs. Gilead said it plans to finance the transaction with a combination of cash on hand and senior unsecured notes. Gilead finished 2025 with $10.605 billion of cash, cash equivalents and marketable debt securities, up from $9.991 billion as of December 31, 2024.

Dealroom.co
Apr 7th, 2026
Gilead Sciences company information, funding & investors

Gilead Sciences, biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for critical diseases. Here you'll find information about their funding, investors and team.